KINEPOLIS (KIN.BR) Fundamental Analysis & Valuation

EBR:KIN • BE0974274061

Current stock price

26.6 EUR
+0.1 (+0.38%)
Last:

This KIN.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. KIN.BR Profitability Analysis

1.1 Basic Checks

  • In the past year KIN was profitable.
  • In the past year KIN had a positive cash flow from operations.
  • Of the past 5 years KIN 4 years were profitable.
  • Each year in the past 5 years KIN had a positive operating cash flow.
KIN.BR Yearly Net Income VS EBIT VS OCF VS FCFKIN.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • KIN's Return On Assets of 3.99% is fine compared to the rest of the industry. KIN outperforms 73.91% of its industry peers.
  • With an excellent Return On Equity value of 19.38%, KIN belongs to the best of the industry, outperforming 82.61% of the companies in the same industry.
  • KIN has a Return On Invested Capital of 9.92%. This is amongst the best in the industry. KIN outperforms 80.43% of its industry peers.
Industry RankSector Rank
ROA 3.99%
ROE 19.38%
ROIC 9.92%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KIN.BR Yearly ROA, ROE, ROICKIN.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • KIN's Profit Margin of 5.45% is fine compared to the rest of the industry. KIN outperforms 69.57% of its industry peers.
  • In the last couple of years the Profit Margin of KIN has grown nicely.
  • The Operating Margin of KIN (12.02%) is better than 73.91% of its industry peers.
  • KIN's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 21.80%, KIN is not doing good in the industry: 86.96% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of KIN has remained more or less at the same level.
Industry RankSector Rank
OM 12.02%
PM (TTM) 5.45%
GM 21.8%
OM growth 3Y1.62%
OM growth 5YN/A
PM growth 3Y6.79%
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5YN/A
KIN.BR Yearly Profit, Operating, Gross MarginsKIN.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. KIN.BR Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KIN is still creating some value.
  • There is no outstanding debt for KIN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KIN.BR Yearly Shares OutstandingKIN.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KIN.BR Yearly Total Debt VS Total AssetsKIN.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.60, we must say that KIN is in the distress zone and has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.60, KIN is doing good in the industry, outperforming 63.04% of the companies in the same industry.
  • The Debt to FCF ratio of KIN is 7.85, which is on the high side as it means it would take KIN, 7.85 years of fcf income to pay off all of its debts.
  • KIN has a Debt to FCF ratio (7.85) which is comparable to the rest of the industry.
  • KIN has a Debt/Equity ratio of 2.10. This is a high value indicating a heavy dependency on external financing.
  • KIN has a worse Debt to Equity ratio (2.10) than 65.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 7.85
Altman-Z 1.6
ROIC/WACC1.44
WACC6.89%
KIN.BR Yearly LT Debt VS Equity VS FCFKIN.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • KIN has a Current Ratio of 0.55. This is a bad value and indicates that KIN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of KIN (0.55) is worse than 69.57% of its industry peers.
  • A Quick Ratio of 0.53 indicates that KIN may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.53, KIN is not doing good in the industry: 71.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.53
KIN.BR Yearly Current Assets VS Current LiabilitesKIN.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. KIN.BR Growth Analysis

3.1 Past

  • KIN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.95%, which is quite good.
  • KIN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.02% yearly.
  • The Revenue has grown by 42.30% in the past year. This is a very strong growth!
  • The Revenue has been growing by 26.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.95%
EPS 3Y12.02%
EPS 5YN/A
EPS Q2Q%-2.81%
Revenue 1Y (TTM)42.3%
Revenue growth 3Y4.16%
Revenue growth 5Y26.23%
Sales Q2Q%68.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.40% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 7.29% on average over the next years.
EPS Next Y43.44%
EPS Next 2Y27.47%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue Next Year20.41%
Revenue Next 2Y12.88%
Revenue Next 3Y8.17%
Revenue Next 5Y7.29%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
KIN.BR Yearly Revenue VS EstimatesKIN.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
KIN.BR Yearly EPS VS EstimatesKIN.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. KIN.BR Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.93 indicates a correct valuation of KIN.
  • Compared to the rest of the industry, the Price/Earnings ratio of KIN indicates a rather cheap valuation: KIN is cheaper than 89.13% of the companies listed in the same industry.
  • KIN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.60.
  • With a Price/Forward Earnings ratio of 10.88, the valuation of KIN can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, KIN is valued cheaper than 89.13% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, KIN is valued rather cheaply.
Industry RankSector Rank
PE 15.93
Fwd PE 10.88
KIN.BR Price Earnings VS Forward Price EarningsKIN.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • KIN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. KIN is cheaper than 67.39% of the companies in the same industry.
  • 82.61% of the companies in the same industry are more expensive than KIN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.68
EV/EBITDA 7.36
KIN.BR Per share dataKIN.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • KIN has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as KIN's earnings are expected to grow with 24.40% in the coming years.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y27.47%
EPS Next 3Y24.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. KIN.BR Dividend Analysis

5.1 Amount

  • KIN has a Yearly Dividend Yield of 1.81%.
  • KIN's Dividend Yield is a higher than the industry average which is at 1.06.
  • Compared to an average S&P500 Dividend Yield of 1.88, KIN has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.81%

5.2 History

  • The dividend of KIN decreases each year by -3.24%.
Dividend Growth(5Y)-3.24%
Div Incr Years1
Div Non Decr Years2
KIN.BR Yearly Dividends per shareKIN.BR Yearly Dividends per shareYearly Dividends per share 2019 2020 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • KIN pays out 32.78% of its income as dividend. This is a sustainable payout ratio.
DP32.78%
EPS Next 2Y27.47%
EPS Next 3Y24.4%
KIN.BR Yearly Income VS Free CF VS DividendKIN.BR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M
KIN.BR Dividend Payout.KIN.BR Dividend Payout, showing the Payout Ratio.KIN.BR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

KIN.BR Fundamentals: All Metrics, Ratios and Statistics

KINEPOLIS

EBR:KIN (4/2/2026, 7:00:00 PM)

26.6

+0.1 (+0.38%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)02-20
Earnings (Next)N/A
Inst Owners16.13%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner ChangeN/A
Market Cap728.04M
Revenue(TTM)822.78M
Net Income(TTM)44.88M
Analysts86
Price Target45.78 (72.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.81%
Yearly Dividend0.55
Dividend Growth(5Y)-3.24%
DP32.78%
Div Incr Years1
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.14%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-7.86%
EPS NY rev (3m)-8.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 15.93
Fwd PE 10.88
P/S 0.88
P/FCF 7.68
P/OCF 5.25
P/B 3.14
P/tB 13.77
EV/EBITDA 7.36
EPS(TTM)1.67
EY6.28%
EPS(NY)2.45
Fwd EY9.2%
FCF(TTM)3.46
FCFY13.02%
OCF(TTM)5.07
OCFY19.05%
SpS30.06
BVpS8.46
TBVpS1.93
PEG (NY)0.37
PEG (5Y)N/A
Graham Number17.83
Profitability
Industry RankSector Rank
ROA 3.99%
ROE 19.38%
ROCE 13.36%
ROIC 9.92%
ROICexc 12.41%
ROICexgc 17.78%
OM 12.02%
PM (TTM) 5.45%
GM 21.8%
FCFM 11.52%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y1.62%
OM growth 5YN/A
PM growth 3Y6.79%
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5YN/A
F-Score7
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 7.85
Debt/EBITDA 2.71
Cap/Depr 54.31%
Cap/Sales 5.34%
Interest Coverage 4.68
Cash Conversion 77.15%
Profit Quality 211.16%
Current Ratio 0.55
Quick Ratio 0.53
Altman-Z 1.6
F-Score7
WACC6.89%
ROIC/WACC1.44
Cap/Depr(3y)49.94%
Cap/Depr(5y)40.94%
Cap/Sales(3y)7.03%
Cap/Sales(5y)6.61%
Profit Quality(3y)253.44%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.95%
EPS 3Y12.02%
EPS 5YN/A
EPS Q2Q%-2.81%
EPS Next Y43.44%
EPS Next 2Y27.47%
EPS Next 3Y24.4%
EPS Next 5YN/A
Revenue 1Y (TTM)42.3%
Revenue growth 3Y4.16%
Revenue growth 5Y26.23%
Sales Q2Q%68.42%
Revenue Next Year20.41%
Revenue Next 2Y12.88%
Revenue Next 3Y8.17%
Revenue Next 5Y7.29%
EBIT growth 1Y20.48%
EBIT growth 3Y5.85%
EBIT growth 5YN/A
EBIT Next Year129.3%
EBIT Next 3Y39.36%
EBIT Next 5Y22.96%
FCF growth 1Y-21.7%
FCF growth 3Y-4.34%
FCF growth 5YN/A
OCF growth 1Y-15.27%
OCF growth 3Y0.65%
OCF growth 5YN/A

KINEPOLIS / KIN.BR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for KINEPOLIS?

ChartMill assigns a fundamental rating of 5 / 10 to KIN.BR.


Can you provide the valuation status for KINEPOLIS?

ChartMill assigns a valuation rating of 8 / 10 to KINEPOLIS (KIN.BR). This can be considered as Undervalued.


How profitable is KINEPOLIS (KIN.BR) stock?

KINEPOLIS (KIN.BR) has a profitability rating of 6 / 10.


What is the financial health of KINEPOLIS (KIN.BR) stock?

The financial health rating of KINEPOLIS (KIN.BR) is 2 / 10.


Is the dividend of KINEPOLIS sustainable?

The dividend rating of KINEPOLIS (KIN.BR) is 4 / 10 and the dividend payout ratio is 32.78%.